X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (165) 165
female (110) 110
male (103) 103
middle aged (102) 102
adult (101) 101
hematology (85) 85
aged (50) 50
oncology (50) 50
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
transplantation, autologous (47) 47
adolescent (46) 46
index medicus (38) 38
bone marrow transplantation (37) 37
transplantation (32) 32
combined modality therapy (30) 30
chemotherapy (29) 29
hematopoietic stem cell transplantation (29) 29
treatment outcome (24) 24
child (22) 22
survival (20) 20
cytarabine - administration & dosage (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - therapy (18) 18
remission induction (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
care and treatment (16) 16
disease-free survival (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (16) 16
therapy (16) 16
stem cells (15) 15
transplantation, homologous (15) 15
chronic myelogenous leukemia (14) 14
immunology (14) 14
prognosis (14) 14
endocrinology & metabolism (13) 13
etoposide - administration & dosage (13) 13
follow-up studies (13) 13
hematopoietic stem cells (13) 13
hodgkin disease - therapy (13) 13
retrospective studies (13) 13
animals (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (12) 12
clinical trials as topic (12) 12
health aspects (12) 12
idarubicin - administration & dosage (12) 12
italy (12) 12
acute disease (11) 11
antineoplastic agents - therapeutic use (11) 11
bone-marrow transplantation (11) 11
child, preschool (11) 11
hematopoietic stem cell transplantation - methods (11) 11
leukapheresis (11) 11
leukemia, myeloid, acute - therapy (11) 11
recurrence (11) 11
survival rate (11) 11
leukemia, myeloid, acute - surgery (10) 10
lymphomas (10) 10
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (10) 10
precursor cell lymphoblastic leukemia-lymphoma - therapy (10) 10
research (10) 10
time factors (10) 10
aged, 80 and over (9) 9
cancer (9) 9
cyclophosphamide - administration & dosage (9) 9
diagnosis (9) 9
granulocyte colony-stimulating factor - therapeutic use (9) 9
medicine & public health (9) 9
multiple myeloma (9) 9
prospective studies (9) 9
rituximab (9) 9
survival analysis (9) 9
bone-marrow-transplantation (8) 8
chronic myeloid-leukemia (8) 8
dosage and administration (8) 8
hodgkin disease - drug therapy (8) 8
idarubicin (8) 8
leukemia (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - genetics (8) 8
leukemia, myeloid, acute - drug therapy (8) 8
leukemia, myeloid, acute - mortality (8) 8
multiple myeloma - mortality (8) 8
myelodysplastic syndromes (8) 8
patient outcomes (8) 8
prednisone - administration & dosage (8) 8
relapse (8) 8
remission (8) 8
salvage therapy (8) 8
stem cell transplantation (8) 8
stem-cell transplantation (8) 8
young adult (8) 8
acute myelogenous leukemia (7) 7
age factors (7) 7
cyclophosphamide (7) 7
doxorubicin - administration & dosage (7) 7
drug therapy (7) 7
drug therapy, combination (7) 7
gene expression (7) 7
hodgkin disease - surgery (7) 7
infant (7) 7
interferon-alpha - therapeutic use (7) 7
leukemia - drug therapy (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
Blood, ISSN 0006-4971, 11/2007, Volume 110, Issue 11, pp. 4555 - 4555
Cytotoxic lymphocytes (CTLs) which recognize distinct antigenic peptides on CML cells, contributed greatly to the cure after allografting. Previously, BCR-ABL... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1733 - 1747
Journal Article
Leukemia, ISSN 0887-6924, 06/2016, Volume 30, Issue 6, pp. 1320 - 1326
Journal Article
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1547 - 1553
Background: Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly... 
hypomethylating treatment | allogeneic stem-cell transplantation | high-risk MDS | azacitidine | SURVIVAL | AML | PROGNOSTIC SCORING SYSTEM | EFFICACY | CLASSIFICATION | CHEMOTHERAPY | CONVENTIONAL CARE REGIMENS | ONCOLOGY | MDS | AGE | Azacitidine - adverse effects | Prospective Studies | Humans | Middle Aged | Male | Hematopoietic Stem Cell Transplantation - mortality | Transplantation Conditioning - mortality | Transplantation, Homologous | Antimetabolites, Antineoplastic - administration & dosage | Feasibility Studies | Young Adult | Myelodysplastic Syndromes - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Leukemia, Myelomonocytic, Chronic - pathology | Transplantation Conditioning - methods | Leukemia, Myeloid, Acute - therapy | Azacitidine - administration & dosage | Drug Administration Schedule | Leukemia, Myeloid, Acute - pathology | Leukemia, Myelomonocytic, Chronic - mortality | Risk Factors | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - adverse effects | Leukemia, Myelomonocytic, Chronic - therapy | Myelodysplastic Syndromes - mortality | Survival Analysis | Italy | Aged | Myelodysplastic Syndromes - pathology
Journal Article
Annals of Hematology, ISSN 0939-5555, 8/2018, Volume 97, Issue 8, pp. 1301 - 1315
The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of... 
New salvage treatments | Oncology | Allografting | Medicine & Public Health | Hematology | Relapsed/refractory Hodgkin lymphoma | BONE-MARROW-TRANSPLANTATION | PD-1 BLOCKADE | PHASE-II | STAGE-III | WORKING PARTY | RADIATION-THERAPY | POSITRON-EMISSION-TOMOGRAPHY | POSTTRANSPLANTATION CYCLOPHOSPHAMIDE | RESPONSE-ADAPTED THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Antineoplastic Agents, Immunological - administration & dosage | Doxorubicin - therapeutic use | Immunomodulation - drug effects | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Positron-Emission Tomography | Vinblastine - therapeutic use | Molecular Targeted Therapy | Immunoconjugates - administration & dosage | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Immunoconjugates - therapeutic use | Immunoconjugates - adverse effects | Hodgkin Disease - diagnosis | Treatment Outcome | Combined Modality Therapy | Bleomycin - adverse effects | Retreatment | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - immunology | Neoplasm Staging | Doxorubicin - adverse effects | Care and treatment | Lymphomas | Transplantation | Drug therapy | Stem cells | Cancer | Index Medicus
Journal Article
by Castagnetti, Fausto and Gugliotta, G and Baccarani, M and Breccia, M and Specchia, G and Levato, L and Abruzzese, E and Rossi, G and Iurlo, A and Martino, B and Pregno, P and Stagno, F and Cuneo, A and Bonifacio, M and Gobbi, M and Russo, D and Gozzini, A and Tiribelli, M and De Vivo, A and Alimena, G and Cavo, M and Martinelli, G and Pane, F and Saglio, G and Rosti, G and Salvi, F and Pini, M and Leoni, P and Rupoli, S and Galieni, P and Bigazzi, C and Cantore, N and Palmieri, F and Albano, F and Russo Rossi, A and Rambaldi, A and Intermesoli, T and Palandri, F and Testoni, N and Luatti, S and Soverini, S and Iacobucci, I and Bochicchio, M.T and Apolinari, M and Fogli, M and Cervello, I and Capucci, A and Malagola, M and Malpignano, A and Girasoli, M and Angelucci, E and Usala, E and Storti, S and De Biasi, E and Tagariello, G and Sartori, R and Di Raimondo, F and Vigneri, P and Impera, S and Molica, S and Lanza, F and Viganò, C and Grasso, M and Rapezzi, D and Cavazzini, F and Bosi, A and Santini, V and Capalbo, S.F and Spinosa, G and Pierri, I and Bergamaschi, M and Carella, A.M and Bacigalupo, A and De Blasio, A and Ciccone, F and Di Renzo, N and Musolino, C and Russo, S and Cortelezzi, A and Morra, E and Pungolino, E.M and Luppi, M and Marasca, R and Pogliani, E.M and Gambacorti-Passerini, C and Luciano, L and Ferrara, F and Annunziata, M and Latte, G and Noli, D and Rege-Cambrin, G and Fava, C and Semenzato, G and Binotto, G and Fabbiano, F and Turri, D and Siragusa, S and Caracciolo, C and Musso, M and Porretto, F and ... and GIMEMA CML Working Party
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 185 - 192
Journal Article